Italia markets open in 7 hours 19 minutes

Bristol-Myers Squibb Company (BMY)

NYSE - Nasdaq Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
49,38+0,66 (+1,35%)
Alla chiusura: 04:00PM EST
49,50 +0,12 (+0,24%)
Dopo ore: 07:35PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente48,72
Aperto48,78
Denaro49,31 x 900
Lettera49,78 x 1800
Min-Max giorno48,25 - 49,40
Intervallo di 52 settimane48,25 - 81,44
Volume11.068.202
Media Volume12.835.788
Capitalizzazione100,476B
Beta (5 anni mensile)0,37
Rapporto PE (ttm)12,53
EPS (ttm)3,94
Prossima data utili02 feb 2024
Rendimento e dividendo (futuro)2,28 (4,68%)
Data ex dividendo05 ott 2023
Stima target 1A57,45
  • GlobeNewswire

    Arbutus Appoints Two New Executives

    Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Chri

  • GlobeNewswire

    iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors

    LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close Series A financing at a total of